Skip to content

The effect of Risperidone on child masturbation

Risperidone as a Treatment of Childhood Masturbation

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201110187841N1
Enrollment
90
Registered
2011-11-01
Start date
2009-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Masturbation. Other specified behavioural and emotional disorders with onset usually occurring in childhood and adolescence

Interventions

Intervention 1: Control group: behavioral treatments by distracting the child indirectly from masturbating. Intervention 2: Intervention group: behavioral treatments by distracting the child indirectl
Behavior
Treatment - Drugs
Control group: behavioral treatments by distracting the child indirectly from masturbating.
Intervention group: behavioral treatments by distracting the child indirectly from masturbating and oral Risperidone pill, 0.25 - 1 mg daily for 4 weeks.

Sponsors

Behavioral Sciences Research Center, Department of Psychiatry, Isfahan University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 7 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age of 3 to 7 years; diagnosed with masturbation problems by a psychiatrist; masturbation have had to be seen in the child as a daily habit and parents consent for their child to participate in the study. Exclusion criteria: children suffering from mental disorders; autism and chronic diseases who have needed for continuous drug therapy; children who have been treated for masturbation in the last month and infectious genitalia diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Frequency of daily masturbation. Timepoint: before intervention and once a week during the 4 week period of the study. Method of measurement: filling out the form by parents in home by observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVictoria Omranifard, Psychiatrist, Assistant Professor

Department of Psychiatry, Isfahan University of Medical Sciences

v_omranifard@med.mui.ac.ir , psy_group@mui.ac.ir+98 31 1222 2475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026